A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection

Nicholas J. Barrows, Rafael Kroon Campos, Steven T. Powell, K. Reddisiva Prasanth, Geraldine Schott-Lerner, Ruben Soto-Acosta, Gaddiel Galarza-Munoz, Erica L. McGrath, Rheanna Urrabaz-Garza, Junling Gao, Ping Wu, Ramkumar Menon, George Saade, Ildefonso Fernandez-Salas, Shannan Rossi, Nikos Vasilakis, Andrew Routh, Shelton Bradrick, Mariano Garcia-Blanco

Research output: Contribution to journalArticle

177 Scopus citations

Abstract

Currently there are no approved vaccines or specific therapies to prevent or treat Zika virus (ZIKV) infection. We interrogated a library of FDA-approved drugs for their ability to block infection of human HuH-7 cells by a newly isolated ZIKV strain (ZIKV MEX_I_7). More than 20 out of 774 tested compounds decreased ZIKV infection in our in vitro screening assay. Selected compounds were further validated for inhibition of ZIKV infection in human cervical, placental, and neural stem cell lines, as well as primary human amnion cells. Established anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) and others that had no previously known antiviral activity (e.g., daptomycin) were identified as inhibitors of ZIKV infection. Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis. Currently there is no approved therapy to treat Zika virus (ZIKV) infection. Barrows et al. present a screen of FDA-approved drugs for anti-ZIKV activity in a hepatoma cell line. Selected compounds from the more than 20 identified candidates were validated in human neural stem cells and primary amnion cells.

Original languageEnglish (US)
JournalCell Host and Microbe
DOIs
StateAccepted/In press - May 15 2016

    Fingerprint

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Cancer Research
  • Molecular Biology

Cite this

Barrows, N. J., Kroon Campos, R., Powell, S. T., Prasanth, K. R., Schott-Lerner, G., Soto-Acosta, R., Galarza-Munoz, G., McGrath, E. L., Urrabaz-Garza, R., Gao, J., Wu, P., Menon, R., Saade, G., Fernandez-Salas, I., Rossi, S., Vasilakis, N., Routh, A., Bradrick, S., & Garcia-Blanco, M. (Accepted/In press). A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell Host and Microbe. https://doi.org/10.1016/j.chom.2016.07.004